drugset / Trial / NCT02903381
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Phase 2
Completed
8 enrolled
Dana-Farber Cancer Institute
Blood Cancer Research Partnership · collabBristol-Myers Squibb · collabMultiple Myeloma Research Consortium · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. \- Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.
Timeline
- Start
- 2016-10-20
- Primary completion
- 2018-06-28
- Completion
- 2021-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |